<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01747447</url>
  </required_header>
  <id_info>
    <org_study_id>2012P000560</org_study_id>
    <secondary_id>2R01AR059775-06A1</secondary_id>
    <secondary_id>5R01AR060574-03</secondary_id>
    <nct_id>NCT01747447</nct_id>
  </id_info>
  <brief_title>VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone</brief_title>
  <acronym>VITAL</acronym>
  <official_title>VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D supplements are widely promoted for bone health. Both vitamin D and vitamin K are
      important for deposition of calcium in bone, but little is known about the relationship of
      vitamin K status and bone health.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of VITAL: Interrelationship of Vitamin D and Vitamin K on Bone is to test whether:
      In a case-cohort design of participants with fractures to determine whether vitamin K status
      is associated with incident fractures or bone health outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fractures</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether low vitamin K status is associated with changed incident total, non-vertebral, and hip fractures as assessed by annual questionnaires, medical record review, and fracture adjudication.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractures</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether effects of vitamin D supplementation vs. placebo on incident total, non-vertebral, and hip fractures are attenuated in the presence of low baseline vitamin K status as assessed by annual questionnaires, medical record review, and fracture adjudication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal Bone Mineral Density</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether low vitamin K status at baseline is associated with changed areal bone mineral density, as assessed by dual-energy X-ray absorptiometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric Bone Mineral Density</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether low vitamin K status at baseline is associated with changed volumetric bone mineral density, as assessed by peripheral quantitative computed tomography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Structural Deterioration</measure>
    <time_frame>2 years</time_frame>
    <description>To determine whether low vitamin K status at baseline is associated with bone structural deterioration, as assessed by Trabecular Bone Score, a textural analysis of bone (higher score is better, scoring: ≥1.350 is &quot;normal microarchitecture,&quot; 1.200-1.350 is &quot;partially degraded microarchitecture,&quot; and ≤1.200 is &quot;degraded microarchitecture.&quot;)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">771</enrollment>
  <condition>Bone Density</condition>
  <condition>Bone Health</condition>
  <condition>Fractures</condition>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3 placebo</intervention_name>
    <description>Vitamin D placebo</description>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil placebo</intervention_name>
    <description>Fish oil placebo</description>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 fatty acids (fish oil)</intervention_name>
    <description>Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D placebo + fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 (cholecalciferol), 2000 IU per day.</description>
    <arm_group_label>Vitamin D + fish oil</arm_group_label>
    <arm_group_label>Vitamin D + fish oil placebo</arm_group_label>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Participants in VITAL (NCT 01169259) who meet the following criteria are eligible to
        participate in this ancillary study:

          -  Those who are using bisphosphonates currently or within the past 2 years, or other
             bone-active medications currently or within the past year are not eligible for this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meryl S LeBoff, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org/</url>
    <description>VITAL Study Website</description>
  </link>
  <reference>
    <citation>LeBoff MS, Yue AY, Copeland T, Cook NR, Buring JE, Manson JE. VITAL-Bone Health: rationale and design of two ancillary studies evaluating the effects of vitamin D and/or omega-3 fatty acid supplements on incident fractures and bone health outcomes in the VITamin D and OmegA-3 TriaL (VITAL). Contemp Clin Trials. 2015 Mar;41:259-68. doi: 10.1016/j.cct.2015.01.007. Epub 2015 Jan 24.</citation>
    <PMID>25623291</PMID>
  </reference>
  <reference>
    <citation>Donlon CM, LeBoff MS, Chou SH, Cook NR, Copeland T, Buring JE, Bubes V, Kotler G, Manson JE. Baseline characteristics of participants in the VITamin D and OmegA-3 TriaL (VITAL): Effects on Bone Structure and Architecture. Contemp Clin Trials. 2018 Apr;67:56-67. doi: 10.1016/j.cct.2018.02.003. Epub 2018 Feb 23.</citation>
    <PMID>29408561</PMID>
  </reference>
  <reference>
    <citation>Goldman AL, Donlon CM, Cook NR, Manson JE, Buring JE, Copeland T, Yu CY, LeBoff MS. VITamin D and OmegA-3 TriaL (VITAL) bone health ancillary study: clinical factors associated with trabecular bone score in women and men. Osteoporos Int. 2018 Nov;29(11):2505-2515. doi: 10.1007/s00198-018-4633-3. Epub 2018 Jul 18.</citation>
    <PMID>30022253</PMID>
  </reference>
  <reference>
    <citation>LeBoff MS, Chou SH, Murata EM, Donlon CM, Cook NR, Mora S, Lee IM, Kotler G, Bubes V, Buring JE, Manson JE. Effects of Supplemental Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL (VITAL). J Bone Miner Res. 2020 May;35(5):883-893. doi: 10.1002/jbmr.3958. Epub 2020 Jan 30.</citation>
    <PMID>31923341</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Meryl LeBoff</investigator_full_name>
    <investigator_title>Director of Skeletal Health and Osteoporosis Center</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin K</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

